European Commission logo
English English
CORDIS - EU research results
CORDIS

Harmless Clostridium bacteria as a highly targeted, continuous delivery system for immunomodulatory anti-cancer drugs

Deliverables

training program oncology

D1.1 Report on training program oncology (M12)

training program business aspects

D1.2 Report on training program business aspects (M12)

Publications

Spores of <i>Clostridium</i> engineered for clinical efficacy and safety cause regression and cure of tumors <i>in vivo</i>

Author(s): John T. Heap, Jan Theys, Muhammad Ehsaan, Aleksandra M Kubiak, Ludwig Dubois, Kim Paesmans, Lieve Van Mellaert, Richard Knox, Sarah A. Kuehne, Phillipe Lambin, Nigel P. Minton
Published in: Oncotarget, Issue 5/7, 2014, ISSN 1949-2553
Publisher: Impact Journals
DOI: 10.18632/oncotarget.1761

The potential of clostridial spores as therapeutic delivery vehicles in tumour therapy

Author(s): Aleksandra M. Kubiak, Nigel P. Minton
Published in: Research in Microbiology, Issue 166/4, 2015, Page(s) 244-254, ISSN 0923-2508
Publisher: Elsevier BV
DOI: 10.1016/j.resmic.2014.12.006

Advancing Clostridia to Clinical Trial: Past Lessons and Recent Progress

Author(s): Alexandra Mowday, Christopher Guise, David Ackerley, Nigel Minton, Philippe Lambin, Ludwig Dubois, Jan Theys, Jeff Smaill, Adam Patterson
Published in: Cancers, Issue 8/7, 2016, Page(s) 63, ISSN 2072-6694
Publisher: Multidisciplinary Digital Publishing Institute (MDPI)
DOI: 10.3390/cancers8070063

Searching for OpenAIRE data...

There was an error trying to search data from OpenAIRE

No results available